Newest Coronavirus Information
WEDNESDAY, April 27, 2022 (HealthDay Information)
Pfizer Inc. introduced Tuesday that it has requested the U.S. Meals and Drug Administration to approve emergency use of its booster shot for kids ages 5 to 11.
The appliance hinges on a research of 140 kids with no proof of prior coronavirus an infection. Their antibody ranges towards the unique pressure of the virus have been six occasions greater a month after a booster dose than a month after a second dose, the corporate stated in a news release.
A 3rd dose boosted antibodies towards the Omicron variant by 36 occasions in kids ages 5-11, the businesses reported earlier this month..
An preliminary two-dose collection of the Pfizer vaccine was authorized for that age group in October.
First boosters of the vaccine are licensed for adults and sure immunocompromised kids aged 12 and older. Second boosters are authorized for anybody 50 and older.
The effectiveness of two doses of the Pfizer vaccine in stopping an infection in kids ages 5-12 fell from 68% to about 12% through the Omicron surge, however nonetheless offered safety towards extreme sickness, in line with research by the U.S. Facilities for Illness Management and Prevention and the New York State Department of Health.
Kids youthful than 5 are the one age group in america for which a COVID-19 shot isn’t licensed, however Pfizer is conducting worldwide clinical trials with greater than 100,000 kids ages 6 months to 12 years, and plans to submit information to plenty of regulatory businesses for authorization within the coming weeks, CNN reported.
Extra info
Go to the U.S. Facilities for Illness Management and Prevention for extra on COVID vaccines for kids.
SOURCE: Pfizer, information launch, April 26, 2022; The New York Occasions
By Robert Preidt and Robin Foster HealthDay Reporters
Copyright © 2021 HealthDay. All rights reserved.
